288 related articles for article (PubMed ID: 21839418)
21. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer.
Garrison LP; Veenstra DL
Value Health; 2009; 12(8):1118-23. PubMed ID: 19624617
[TBL] [Abstract][Full Text] [Related]
22. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme.
Claxton K; Ginnelly L; Sculpher M; Philips Z; Palmer S
Health Technol Assess; 2004 Jul; 8(31):1-103, iii. PubMed ID: 15248937
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review.
Chan AL; Leung HW; Lu CL; Lin SJ
Ann Pharmacother; 2009 Feb; 43(2):296-303. PubMed ID: 19193576
[TBL] [Abstract][Full Text] [Related]
24. Economic evaluation of diagnostic technology. Methodological challenges and viable solutions.
Sassi F; McKee M; Roberts JA
Int J Technol Assess Health Care; 1997; 13(4):613-30. PubMed ID: 9489253
[TBL] [Abstract][Full Text] [Related]
25. Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework.
Tappenden P; Chilcott J; Brennan A; Squires H; Stevenson M
Value Health; 2012 Dec; 15(8):1127-36. PubMed ID: 23244816
[TBL] [Abstract][Full Text] [Related]
26. SOCIO-ETHICAL ISSUES IN PERSONALIZED MEDICINE: A SYSTEMATIC REVIEW OF ENGLISH LANGUAGE HEALTH TECHNOLOGY ASSESSMENTS OF GENE EXPRESSION PROFILING TESTS FOR BREAST CANCER PROGNOSIS.
Ali-Khan SE; Black L; Palmour N; Hallett MT; Avard D
Int J Technol Assess Health Care; 2015 Jan; 31(1-2):36-50. PubMed ID: 25991501
[TBL] [Abstract][Full Text] [Related]
27. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
[TBL] [Abstract][Full Text] [Related]
28. The Role of Measurement Uncertainty in Health Technology Assessments (HTAs) of In Vitro Tests.
Smith AF; Messenger M; Hall P; Hulme C
Pharmacoeconomics; 2018 Jul; 36(7):823-835. PubMed ID: 29502176
[TBL] [Abstract][Full Text] [Related]
29. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
[TBL] [Abstract][Full Text] [Related]
30. The value of value of information: best informing research design and prioritization using current methods.
Eckermann S; Karnon J; Willan AR
Pharmacoeconomics; 2010; 28(9):699-709. PubMed ID: 20629473
[TBL] [Abstract][Full Text] [Related]
31. Supporting the Development of Evidence-Informed Policy Options: An Economic Evaluation of Hypertension Management in Ghana.
Gad M; Lord J; Chalkidou K; Asare B; Lutterodt MG; Ruiz F
Value Health; 2020 Feb; 23(2):171-179. PubMed ID: 32113622
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
33. An equity framework for health technology assessments.
Culyer AJ; Bombard Y
Med Decis Making; 2012; 32(3):428-41. PubMed ID: 22065143
[TBL] [Abstract][Full Text] [Related]
34. Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013.
Charokopou M; Sabater FJ; Townsend R; Roudaut M; McEwan P; Verheggen BG
Curr Med Res Opin; 2016; 32(2):207-18. PubMed ID: 26473650
[TBL] [Abstract][Full Text] [Related]
35. Evaluations of public health interventions produced by health technology assessment agencies: A mapping review and analysis by type and evidence content.
Cyr PR; Jain V; Chalkidou K; Ottersen T; Gopinathan U
Health Policy; 2021 Aug; 125(8):1054-1064. PubMed ID: 34112508
[TBL] [Abstract][Full Text] [Related]
36. British clinic is allowed to deny medicine; decision on cost has broad impact.
Lyall S
N Y Times Web; 2006 Feb; ():A10. PubMed ID: 16514743
[No Abstract] [Full Text] [Related]
37. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997.
Cooper N; Coyle D; Abrams K; Mugford M; Sutton A
J Health Serv Res Policy; 2005 Oct; 10(4):245-50. PubMed ID: 16259692
[TBL] [Abstract][Full Text] [Related]
38. [Which medico-economic approaches must be taken to evaluate the impact of costly molecules in oncology? The model of Herceptin in the breast metastatic cancer].
Ganne C; Trillet-Lenoir V; Jaisson-Hot I; Chauvin F; Clippe C; Heilmann MO; Hajri T; Poncet B; Heuclin C; Colin C
Bull Cancer; 2003 Nov; 90(11):955-60. PubMed ID: 14706898
[TBL] [Abstract][Full Text] [Related]
39. Health Technology Assessments in Radiology in Germany: Lack of Demand, Lack of Supply.
Winkelmann C; Neumann T; Zeidler J; Prenzler A; Vogt B; Wacker FK
Rofo; 2019 Jul; 191(7):635-642. PubMed ID: 30763963
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
